加载中
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
前收盘价
US$4.84
−US$0.08 · -1.63%
盘前
US$5.1948
+US$0.3548 · +7.33%
10月13日 4:26 ET
盘中时间采用ET。市场数据可能有所延迟。
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
日内区间
当前US$4.84
52周区间
当前US$4.84
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
32
偏贵
情绪
50
多空交织
风险
32
中等风险
动量
65
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Savara Inc. is a biopharmaceutical firm in the clinical development phase, specializing in therapies for uncommon respiratory conditions. Their primary investigational drug, molgramostim, is an inhaled form of granulocyte-macrophage colony-stimulating factor (GM-CSF). This compound is currently undergoing Phase III trials to address autoimmune pulmonary alveolar proteinosis. The company's main operations are situated in Austin, Texas.
日内区间
当前US$4.84
52周区间
当前US$4.84
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 24.5万 USD | 7802.9万 USD | 4426.2万 USD | 2787.9万 USD | 2899.1万 USD |
| 毛利 | −24.5万 USD | −7802.9万 USD | −4426.2万 USD | −2787.9万 USD | −2899.1万 USD |
| 研究与开发 | 8140.4万 USD | 7802.9万 USD | 4426.2万 USD | 2787.9万 USD | 2899.1万 USD |
| 销售、一般及管理费用 | 4205.6万 USD | 2503.7万 USD | 1566.8万 USD | 1092.9万 USD | 1235万 USD |
| 营业费用 | 1.23亿 USD | 2516.7万 USD | 1574.5万 USD | 1096万 USD | 1248.6万 USD |
| 利息收入 | 416.2万 USD | 646.7万 USD | 443.6万 USD | 88 USD | 2282 USD |
| 利息支出 | — | — | — | 8.8万 USD | 228.2万 USD |
| 折旧和摊销 | 8.7万 USD | 13万 USD | 7.7万 USD | 16.7万 USD | 36.7万 USD |
| 营业利润 | −1.24亿 USD | −1.03亿 USD | −6000.7万 USD | −3883.9万 USD | −4147.7万 USD |
| 净利润 | −1.19亿 USD | −9588.1万 USD | −5469.8万 USD | −3815万 USD | −4301.4万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI3322.91万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1969.49万0.03%787.4亿 USD0.19%US$277.9-0.37%
State Street SPDR S&P Biotech ETFXBI1542.08万0.16%103.03亿 USD0.35%US$151.4-1.54%
Vanguard Extended Market ETFVXF856.59万0.01%954亿 USD0.05%US$233.52-0.63%
iShares Russell 2000 Growth ETFIWO690.74万0.05%139.17亿 USD0.24%US$353.71-0.86%
Vanguard Russell 2000 ETFVTWO473.51万0.03%180亿 USD0.06%US$112.27-0.35%
iShares Biotechnology ETFIBB392.64万0.04%108.2亿 USD0.44%US$204.26-1.08%
Schwab U.S. Small-Cap ETFSCHA389.09万0.02%218.24亿 USD0.03%US$32.66-0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
